Investors Capital Advisory Services’s Viridian Therapeutics VRDN Stock Holding History

Investors Capital Advisory Services’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$16K	Hold	174	–	–	﹤0.01%	703
2016 Q1	$20K	Buy	174 +4	+2%	+$511	﹤0.01%	678
2015 Q4	$28K	Buy	170 +71	+72%	+$13.7K	0.01%	694
2015 Q3	$20K	Buy	+99	New	+$34.8K	﹤0.01%	702

Other funds holding VRDN

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Investors Capital Advisory Services's VRDN Position: Q2 2016 in Review

Investors Capital Advisory Services held its Viridian Therapeutics (VRDN) position steady in Q2 2016 at 174 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #703.

Investors Capital Advisory Services first reported a position in VRDN in Q3 2015 and has held it in 4 quarters since. The position peaked at $28K in Q4 2015. 9 funds tracked by Wall St. Rank hold VRDN as of Q2 2016.

Investors Capital Advisory Services held 174 shares of Viridian Therapeutics worth $16K as of Q2 2016.
Investors Capital Advisory Services left its Viridian Therapeutics share count unchanged in Q2 2016.
Viridian Therapeutics made up ﹤0.01% of Investors Capital Advisory Services's portfolio in Q2 2016, its #703 holding.
Investors Capital Advisory Services first reported a position in Viridian Therapeutics in Q3 2015 and has held it in 4 quarters since.
Investors Capital Advisory Services's Viridian Therapeutics position peaked at $28K in Q4 2015.
9 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2016.

Based on Investors Capital Advisory Services's 13F filing for Q2 2016, filed 2 Aug 2016.